PainReform Ltd. (PRFX)
| Previous close | 0.7640 |
| Open | 0.7000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.7000 - 0.7000 |
| 52-week range | 0.4170 - 26.4100 |
| Volume | |
| Avg. volume | 148,019 |
| Market cap | 1.732M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available in the market. These findings underscore PainReform’s commitment to advancing non-opiate pain relief options and mark a significant milestone in developing long-lasting pain management solutions. Leveraging the latest IVR technology, which automates the testing of drug release from formulations over
- Benzinga
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug
On Tuesday, PainReform Ltd (NASDAQ:PRFX) announced it reached the 50% enrollment target for the second part of the Phase 3 clinical trial of PRF-110 in bunionectomy. A bunion is a bony bump that forms at the base of the big toe, forming a union with a foot bone called the first metatarsal. The bunion is a foot deformity comprising bone and soft tissue. Bunion removal is a surgical procedure that corrects a deformed area of the foot near the big toe. Bunion removal is sometimes called a bunionect
- Simply Wall St.
Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
